Literature DB >> 8774574

HIV infection and neoplasia.

T F Schulz1, C H Boshoff, R A Weiss.   

Abstract

HIV infection predisposes to several neoplastic conditions, especially non-Hodgkin lymphoma (NHL) and Kaposi's sarcoma (KS), and also intraepithelial cervical neoplasia (CIN) and anal neoplasia (AIN) (but not cervical or anal invasive cancer) and possibly seminoma. For neoplasias associated with oncogenic human viruses (ie, some NHL, CIN, AIN, and probably KS) the role of HIV is most probably linked to its immunosuppressive effect and interference with immune-mediated tumour surveillance. HIV-1, through its regulatory protein tat, might also have a direct promoting effect on KS lesions but it is not essential for their development. The increased frequency of Burkitt's lymphoma and Epstein-Barr-virus-negative large-cell lymphoma in AIDS patients, but not in immunosuppressed transplant patients, and the increased rate of testicular tumours in HIV-infected individuals remain unexplained and may indicate either a direct role for HIV or other cofactors.

Entities:  

Mesh:

Year:  1996        PMID: 8774574     DOI: 10.1016/S0140-6736(95)11033-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues.

Authors:  M Teitell; M A Damore; G G Sulur; D E Turner; M H Stern; J W Said; C T Denny; R Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 2.  Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 3.  Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen.

Authors:  Kelly M Robinson; Julie C Dunning Hotopp
Journal:  Cancer Lett       Date:  2014-06-21       Impact factor: 8.679

4.  Cervical dysplasia and HIV type 1 infection in African pregnant women: a cross sectional study, Kigali, Rwanda. The Pregnancy and HIV Study Group (EGE).

Authors:  V Leroy; J Ladner; A De Clercq; A Meheus; M Nyiraziraje; E Karita; F Dabis
Journal:  Sex Transm Infect       Date:  1999-04       Impact factor: 3.519

5.  Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection.

Authors:  M Iwashiro; R J Messer; K E Peterson; I M Stromnes; T Sugie; K J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

Review 6.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

7.  Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.

Authors:  Joseph C Alvarnas; Jennifer Le Rademacher; Yanli Wang; Richard F Little; Gorgun Akpek; Ernesto Ayala; Steven Devine; Robert Baiocchi; Gerard Lozanski; Lawrence Kaplan; Ariela Noy; Uday Popat; Jack Hsu; Lawrence E Morris; Jason Thompson; Mary M Horowitz; Adam Mendizabal; Alexandra Levine; Amrita Krishnan; Stephen J Forman; Willis H Navarro; Richard Ambinder
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

Review 8.  Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome.

Authors:  Yan-Mei Huang; Xue-Zhi Hong; Jia-Hua Xu; Jiang-Xi Luo; Han-You Mo; Hai-Lu Zhao
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

9.  The Extended Impact of Human Immunodeficiency Virus/AIDS Research.

Authors:  Tara A Schwetz; Anthony S Fauci
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

Review 10.  Oral manifestations in the era of HAART.

Authors:  Gail Cherry-Peppers; Christine O Daniels; Valli Meeks; Charles F Sanders; David Reznik
Journal:  J Natl Med Assoc       Date:  2003-02       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.